| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 72 | 2025 | 997 | 9.100 |
Why?
|
| Genetic Predisposition to Disease | 68 | 2026 | 681 | 8.390 |
Why?
|
| Polymorphism, Single Nucleotide | 55 | 2026 | 557 | 6.560 |
Why?
|
| CD11b Antigen | 11 | 2019 | 42 | 2.860 |
Why?
|
| Genome-Wide Association Study | 20 | 2025 | 239 | 2.800 |
Why?
|
| Genetic Linkage | 23 | 2012 | 95 | 2.040 |
Why?
|
| Alleles | 27 | 2025 | 357 | 1.970 |
Why?
|
| Genotype | 33 | 2026 | 461 | 1.930 |
Why?
|
| Arthritis, Rheumatoid | 10 | 2020 | 136 | 1.510 |
Why?
|
| Humans | 128 | 2026 | 29078 | 1.390 |
Why?
|
| DNA-Binding Proteins | 9 | 2019 | 490 | 1.330 |
Why?
|
| Case-Control Studies | 26 | 2026 | 740 | 1.310 |
Why?
|
| Haplotypes | 27 | 2026 | 289 | 1.290 |
Why?
|
| Autoimmune Diseases | 6 | 2014 | 170 | 1.280 |
Why?
|
| Gene Frequency | 19 | 2020 | 188 | 1.220 |
Why?
|
| Hidradenitis Suppurativa | 3 | 2025 | 4 | 1.100 |
Why?
|
| Interferon Regulatory Factors | 4 | 2026 | 58 | 1.070 |
Why?
|
| Female | 81 | 2026 | 15740 | 1.040 |
Why?
|
| Male | 70 | 2026 | 14049 | 0.990 |
Why?
|
| Apoptosis | 4 | 2021 | 781 | 0.990 |
Why?
|
| African Americans | 11 | 2013 | 353 | 0.980 |
Why?
|
| Genetic Association Studies | 12 | 2017 | 115 | 0.970 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2025 | 23 | 0.880 |
Why?
|
| Lectins, C-Type | 1 | 2025 | 45 | 0.870 |
Why?
|
| Genetic Variation | 9 | 2019 | 247 | 0.860 |
Why?
|
| Chromosome Mapping | 14 | 2013 | 128 | 0.830 |
Why?
|
| Chronic Pain | 1 | 2025 | 62 | 0.810 |
Why?
|
| DNA Methylation | 1 | 2025 | 153 | 0.800 |
Why?
|
| Sjogren's Syndrome | 2 | 2026 | 278 | 0.800 |
Why?
|
| Biomarkers | 3 | 2025 | 787 | 0.790 |
Why?
|
| Chromosomes, Human, Pair 16 | 6 | 2025 | 20 | 0.780 |
Why?
|
| Polymorphism, Genetic | 9 | 2018 | 166 | 0.770 |
Why?
|
| Guanine Nucleotide Exchange Factors | 2 | 2019 | 30 | 0.720 |
Why?
|
| Autoantibodies | 5 | 2019 | 486 | 0.720 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2021 | 5 | 0.720 |
Why?
|
| Adult | 37 | 2026 | 8080 | 0.710 |
Why?
|
| Pedigree | 21 | 2012 | 155 | 0.660 |
Why?
|
| Disease Susceptibility | 3 | 2019 | 74 | 0.650 |
Why?
|
| Electrophoretic Mobility Shift Assay | 3 | 2019 | 50 | 0.640 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein K | 1 | 2019 | 2 | 0.600 |
Why?
|
| Cell Proliferation | 3 | 2021 | 827 | 0.600 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2019 | 24 | 0.590 |
Why?
|
| DNA | 3 | 2019 | 378 | 0.590 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2019 | 62 | 0.590 |
Why?
|
| Epistasis, Genetic | 4 | 2012 | 24 | 0.570 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2019 | 65 | 0.570 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2019 | 169 | 0.550 |
Why?
|
| Promoter Regions, Genetic | 5 | 2021 | 344 | 0.550 |
Why?
|
| Amino Acid Sequence | 1 | 2019 | 697 | 0.530 |
Why?
|
| Takayasu Arteritis | 1 | 2017 | 5 | 0.520 |
Why?
|
| Interleukin-17 | 1 | 2017 | 52 | 0.510 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2017 | 35 | 0.510 |
Why?
|
| Genetic Markers | 10 | 2012 | 92 | 0.500 |
Why?
|
| Mexico | 5 | 2026 | 92 | 0.500 |
Why?
|
| Odds Ratio | 9 | 2020 | 237 | 0.490 |
Why?
|
| Genetic Loci | 3 | 2017 | 77 | 0.490 |
Why?
|
| Middle Aged | 22 | 2026 | 7458 | 0.470 |
Why?
|
| Interleukin-6 | 1 | 2017 | 198 | 0.470 |
Why?
|
| Quantitative Trait Loci | 3 | 2022 | 56 | 0.460 |
Why?
|
| Phenotype | 13 | 2021 | 688 | 0.460 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 3 | 2013 | 14 | 0.440 |
Why?
|
| NADPH Oxidases | 2 | 2016 | 69 | 0.430 |
Why?
|
| Cohort Studies | 12 | 2019 | 902 | 0.420 |
Why?
|
| Risk Factors | 17 | 2020 | 2138 | 0.420 |
Why?
|
| Interleukin-2 | 2 | 2011 | 35 | 0.400 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 2 | 2023 | 12 | 0.390 |
Why?
|
| Models, Genetic | 11 | 2018 | 126 | 0.390 |
Why?
|
| Chromosomes, Human, Pair 11 | 6 | 2010 | 34 | 0.380 |
Why?
|
| Monocytes | 1 | 2014 | 135 | 0.380 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2013 | 26 | 0.380 |
Why?
|
| Glutathione | 1 | 2012 | 76 | 0.380 |
Why?
|
| Interleukins | 2 | 2011 | 112 | 0.370 |
Why?
|
| Gene Regulatory Networks | 1 | 2012 | 82 | 0.370 |
Why?
|
| Lupus Erythematosus, Discoid | 2 | 2009 | 18 | 0.360 |
Why?
|
| Chromosomes, Human, Pair 13 | 3 | 2008 | 7 | 0.360 |
Why?
|
| Linkage Disequilibrium | 10 | 2016 | 108 | 0.360 |
Why?
|
| RNA, Messenger | 1 | 2014 | 668 | 0.350 |
Why?
|
| Autoimmunity | 3 | 2020 | 158 | 0.340 |
Why?
|
| Chromosomes, Human, Pair 6 | 4 | 2010 | 19 | 0.340 |
Why?
|
| Colombia | 4 | 2011 | 9 | 0.320 |
Why?
|
| Chromosomes, Human, Pair 5 | 3 | 2005 | 10 | 0.320 |
Why?
|
| Mutation | 4 | 2016 | 873 | 0.320 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2010 | 19 | 0.320 |
Why?
|
| Lupus Nephritis | 4 | 2019 | 103 | 0.320 |
Why?
|
| Cleft Lip | 2 | 2007 | 8 | 0.310 |
Why?
|
| Cleft Palate | 2 | 2007 | 15 | 0.310 |
Why?
|
| DNA Mutational Analysis | 5 | 2019 | 93 | 0.310 |
Why?
|
| Chromosomes, Human, Pair 1 | 5 | 2012 | 27 | 0.300 |
Why?
|
| Syncope, Vasovagal | 1 | 2009 | 5 | 0.300 |
Why?
|
| Atrioventricular Block | 1 | 2009 | 8 | 0.300 |
Why?
|
| Aged | 13 | 2026 | 5627 | 0.300 |
Why?
|
| Bradycardia | 1 | 2009 | 17 | 0.300 |
Why?
|
| Adenosine | 1 | 2009 | 33 | 0.300 |
Why?
|
| Lod Score | 12 | 2012 | 36 | 0.290 |
Why?
|
| Vitiligo | 2 | 2001 | 6 | 0.290 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2009 | 117 | 0.290 |
Why?
|
| Computational Biology | 3 | 2021 | 156 | 0.290 |
Why?
|
| Genome, Human | 4 | 2013 | 70 | 0.280 |
Why?
|
| Autophagy | 3 | 2025 | 77 | 0.280 |
Why?
|
| Genes, Dominant | 6 | 2012 | 35 | 0.280 |
Why?
|
| Antigens, Differentiation | 2 | 2005 | 21 | 0.280 |
Why?
|
| Osteopontin | 1 | 2008 | 10 | 0.280 |
Why?
|
| Gene Expression Regulation | 3 | 2017 | 645 | 0.280 |
Why?
|
| Chromatin | 2 | 2022 | 76 | 0.270 |
Why?
|
| Chromosomes, Human, Pair 4 | 2 | 2011 | 16 | 0.270 |
Why?
|
| STAT1 Transcription Factor | 3 | 2018 | 38 | 0.270 |
Why?
|
| Sex Factors | 3 | 2015 | 473 | 0.270 |
Why?
|
| Empyema, Pleural | 1 | 2007 | 3 | 0.270 |
Why?
|
| STAT4 Transcription Factor | 4 | 2018 | 23 | 0.260 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2007 | 6 | 0.260 |
Why?
|
| India | 11 | 2019 | 150 | 0.260 |
Why?
|
| American Native Continental Ancestry Group | 2 | 2017 | 22 | 0.250 |
Why?
|
| Europe | 5 | 2016 | 100 | 0.250 |
Why?
|
| Young Adult | 10 | 2019 | 2855 | 0.250 |
Why?
|
| Adolescent | 13 | 2025 | 3233 | 0.240 |
Why?
|
| Quantitative Trait, Heritable | 4 | 2009 | 15 | 0.240 |
Why?
|
| Microsatellite Repeats | 9 | 2011 | 60 | 0.240 |
Why?
|
| Receptors, Complement 3b | 1 | 2005 | 7 | 0.240 |
Why?
|
| Glomerulonephritis, IGA | 2 | 2016 | 4 | 0.240 |
Why?
|
| B-Lymphocytes | 2 | 2025 | 287 | 0.240 |
Why?
|
| Genome | 1 | 2005 | 58 | 0.230 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 2011 | 13 | 0.230 |
Why?
|
| Interleukin-10 | 1 | 2005 | 74 | 0.230 |
Why?
|
| Wrestling | 1 | 2025 | 8 | 0.230 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2025 | 3 | 0.230 |
Why?
|
| CpG Islands | 1 | 2025 | 26 | 0.220 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2020 | 33 | 0.220 |
Why?
|
| Asian Americans | 3 | 2013 | 40 | 0.220 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 251 | 0.220 |
Why?
|
| Gene Editing | 1 | 2025 | 27 | 0.220 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2025 | 37 | 0.220 |
Why?
|
| Tandem Repeat Sequences | 1 | 2004 | 4 | 0.210 |
Why?
|
| STAT3 Transcription Factor | 1 | 2025 | 97 | 0.210 |
Why?
|
| CRISPR-Cas Systems | 1 | 2025 | 52 | 0.210 |
Why?
|
| Genetic Heterogeneity | 4 | 2016 | 31 | 0.200 |
Why?
|
| Staphylococcal Infections | 1 | 2025 | 90 | 0.200 |
Why?
|
| Ku Autoantigen | 2 | 2014 | 12 | 0.200 |
Why?
|
| Antigens, Nuclear | 2 | 2014 | 22 | 0.200 |
Why?
|
| Protein Binding | 3 | 2015 | 667 | 0.200 |
Why?
|
| Psychotic Disorders | 1 | 2023 | 23 | 0.200 |
Why?
|
| Epigenesis, Genetic | 1 | 2025 | 149 | 0.200 |
Why?
|
| F-Box Proteins | 2 | 2018 | 10 | 0.200 |
Why?
|
| src-Family Kinases | 3 | 2014 | 71 | 0.200 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2017 | 163 | 0.200 |
Why?
|
| United States | 9 | 2016 | 2252 | 0.190 |
Why?
|
| Argentina | 3 | 2016 | 9 | 0.190 |
Why?
|
| Body Mass Index | 3 | 2009 | 416 | 0.190 |
Why?
|
| Foot Deformities, Congenital | 3 | 2006 | 4 | 0.190 |
Why?
|
| Hand Deformities, Congenital | 3 | 2006 | 4 | 0.190 |
Why?
|
| Heredity | 1 | 2022 | 2 | 0.190 |
Why?
|
| Transcription, Genetic | 2 | 2014 | 405 | 0.180 |
Why?
|
| Membrane Proteins | 4 | 2021 | 486 | 0.180 |
Why?
|
| Rural Population | 2 | 2020 | 140 | 0.180 |
Why?
|
| Genetic Diseases, X-Linked | 2 | 2012 | 9 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2001 | 15 | 0.180 |
Why?
|
| Lysine-tRNA Ligase | 1 | 2021 | 3 | 0.180 |
Why?
|
| Myopia | 2 | 2011 | 19 | 0.170 |
Why?
|
| Neonatal Abstinence Syndrome | 1 | 2021 | 10 | 0.170 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2021 | 11 | 0.170 |
Why?
|
| Obesity | 2 | 2009 | 705 | 0.170 |
Why?
|
| Hearing Loss | 1 | 2021 | 39 | 0.170 |
Why?
|
| Hypermedia | 1 | 2000 | 2 | 0.170 |
Why?
|
| Programming Languages | 1 | 2000 | 6 | 0.160 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 44 | 0.160 |
Why?
|
| Blood Pressure | 1 | 2002 | 358 | 0.160 |
Why?
|
| Peritoneal Neoplasms | 2 | 2012 | 80 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2009 | 346 | 0.160 |
Why?
|
| Oxidative Stress | 3 | 2014 | 680 | 0.160 |
Why?
|
| Periodontitis | 1 | 2020 | 11 | 0.160 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 118 | 0.160 |
Why?
|
| Asthma | 1 | 2001 | 61 | 0.160 |
Why?
|
| Protective Factors | 1 | 2019 | 16 | 0.160 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 50 | 0.150 |
Why?
|
| Self Care | 1 | 2019 | 42 | 0.150 |
Why?
|
| Prenatal Care | 1 | 2019 | 47 | 0.150 |
Why?
|
| Child | 8 | 2019 | 2335 | 0.150 |
Why?
|
| Interleukin-18 | 1 | 2019 | 18 | 0.150 |
Why?
|
| HLA Antigens | 2 | 2017 | 61 | 0.150 |
Why?
|
| Amino Acid Substitution | 1 | 2019 | 105 | 0.150 |
Why?
|
| Latin America | 3 | 2015 | 9 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 1 | 2000 | 249 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 105 | 0.140 |
Why?
|
| TCF Transcription Factors | 2 | 2008 | 4 | 0.140 |
Why?
|
| Gene Expression | 2 | 2020 | 417 | 0.140 |
Why?
|
| Galactosyltransferases | 1 | 2018 | 17 | 0.140 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 112 | 0.140 |
Why?
|
| beta Karyopherins | 2 | 2016 | 13 | 0.140 |
Why?
|
| Logistic Models | 3 | 2017 | 415 | 0.140 |
Why?
|
| Nerve Tissue Proteins | 3 | 2012 | 154 | 0.130 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2018 | 49 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2018 | 51 | 0.130 |
Why?
|
| Genetic Load | 1 | 2017 | 6 | 0.130 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2012 | 285 | 0.130 |
Why?
|
| Meta-Analysis as Topic | 2 | 2009 | 33 | 0.130 |
Why?
|
| Ribonuclease H | 1 | 2017 | 1 | 0.130 |
Why?
|
| Chemokine CCL22 | 1 | 2017 | 1 | 0.130 |
Why?
|
| Depression | 1 | 2019 | 229 | 0.130 |
Why?
|
| Autophagy-Related Proteins | 1 | 2017 | 9 | 0.130 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2017 | 14 | 0.130 |
Why?
|
| Toll-Like Receptors | 1 | 2017 | 22 | 0.130 |
Why?
|
| RGS Proteins | 1 | 2016 | 5 | 0.130 |
Why?
|
| Skin Pigmentation | 1 | 2016 | 10 | 0.130 |
Why?
|
| Bayes Theorem | 3 | 2015 | 102 | 0.130 |
Why?
|
| OX40 Ligand | 2 | 2013 | 16 | 0.120 |
Why?
|
| Transcription Factors, TFII | 1 | 2016 | 4 | 0.120 |
Why?
|
| Acne Conglobata | 1 | 2016 | 1 | 0.120 |
Why?
|
| Genes, MHC Class II | 1 | 2016 | 10 | 0.120 |
Why?
|
| HLA-D Antigens | 1 | 2016 | 6 | 0.120 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 21 | 0.120 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2016 | 25 | 0.120 |
Why?
|
| HLA-DRB1 Chains | 1 | 2016 | 33 | 0.120 |
Why?
|
| HLA-C Antigens | 1 | 2015 | 13 | 0.120 |
Why?
|
| Receptors, CCR6 | 1 | 2015 | 2 | 0.120 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2015 | 9 | 0.120 |
Why?
|
| HLA-B Antigens | 1 | 2015 | 29 | 0.120 |
Why?
|
| Age of Onset | 4 | 2018 | 72 | 0.120 |
Why?
|
| Gene Expression Profiling | 4 | 2021 | 477 | 0.120 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2015 | 1 | 0.110 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2015 | 5 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 18 | 2 | 2007 | 13 | 0.110 |
Why?
|
| Mutation, Missense | 2 | 2013 | 71 | 0.110 |
Why?
|
| CTLA-4 Antigen | 2 | 2005 | 11 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2014 | 2070 | 0.110 |
Why?
|
| Oxidation-Reduction | 2 | 2014 | 381 | 0.110 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 149 | 0.110 |
Why?
|
| Chi-Square Distribution | 2 | 2007 | 145 | 0.110 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2014 | 20 | 0.110 |
Why?
|
| Major Histocompatibility Complex | 2 | 2004 | 29 | 0.110 |
Why?
|
| Vitronectin | 1 | 2014 | 3 | 0.110 |
Why?
|
| Animals | 8 | 2021 | 10756 | 0.110 |
Why?
|
| Antigens, CD | 2 | 2005 | 140 | 0.100 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2014 | 9 | 0.100 |
Why?
|
| Macrophages | 1 | 2017 | 306 | 0.100 |
Why?
|
| Fibrinogen | 1 | 2014 | 50 | 0.100 |
Why?
|
| Risk | 1 | 2014 | 138 | 0.100 |
Why?
|
| Nuclear Proteins | 2 | 2012 | 249 | 0.100 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 2013 | 23 | 0.100 |
Why?
|
| Trans-Activators | 1 | 2014 | 118 | 0.100 |
Why?
|
| Transcription Factors | 1 | 2017 | 524 | 0.100 |
Why?
|
| Aluminum Oxide | 1 | 2013 | 10 | 0.100 |
Why?
|
| Interferon-Induced Helicase, IFIH1 | 1 | 2013 | 11 | 0.100 |
Why?
|
| Durapatite | 1 | 2013 | 15 | 0.100 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2013 | 25 | 0.100 |
Why?
|
| Epidemiologic Methods | 2 | 2010 | 21 | 0.100 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2013 | 35 | 0.100 |
Why?
|
| Lipid Peroxidation | 2 | 2014 | 48 | 0.100 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2013 | 30 | 0.100 |
Why?
|
| Materials Testing | 1 | 2013 | 89 | 0.100 |
Why?
|
| Pharmacogenetics | 1 | 2012 | 6 | 0.100 |
Why?
|
| Immune Tolerance | 1 | 2013 | 52 | 0.090 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 1992 | 5 | 0.090 |
Why?
|
| Nystagmus, Congenital | 1 | 2012 | 1 | 0.090 |
Why?
|
| Chromosome Duplication | 1 | 2012 | 1 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 10 | 2 | 2016 | 11 | 0.090 |
Why?
|
| 3' Untranslated Regions | 2 | 2012 | 34 | 0.090 |
Why?
|
| Hernia, Umbilical | 1 | 2012 | 4 | 0.090 |
Why?
|
| Exons | 2 | 2012 | 43 | 0.090 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2012 | 2 | 0.090 |
Why?
|
| Models, Molecular | 1 | 2013 | 453 | 0.090 |
Why?
|
| Colectomy | 1 | 2012 | 5 | 0.090 |
Why?
|
| Antioxidants | 1 | 2014 | 225 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 36 | 0.090 |
Why?
|
| Probability | 2 | 2008 | 78 | 0.090 |
Why?
|
| Cytoskeletal Proteins | 1 | 2012 | 42 | 0.090 |
Why?
|
| Appendectomy | 1 | 2012 | 14 | 0.090 |
Why?
|
| Mitosis | 1 | 2012 | 115 | 0.090 |
Why?
|
| Cell Adhesion Molecules | 1 | 2012 | 69 | 0.090 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 276 | 0.090 |
Why?
|
| Lipids | 2 | 2008 | 220 | 0.090 |
Why?
|
| Chromosomes, Human, X | 1 | 2011 | 38 | 0.090 |
Why?
|
| Pregnancy | 5 | 2021 | 1261 | 0.090 |
Why?
|
| Consanguinity | 2 | 2012 | 5 | 0.090 |
Why?
|
| Confidence Intervals | 2 | 2008 | 69 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 383 | 0.080 |
Why?
|
| Mesothelioma | 1 | 2010 | 4 | 0.080 |
Why?
|
| Dupuytren Contracture | 1 | 2010 | 5 | 0.080 |
Why?
|
| Cell Cycle Proteins | 1 | 2012 | 187 | 0.080 |
Why?
|
| DNA, Neoplasm | 1 | 2010 | 34 | 0.080 |
Why?
|
| ErbB Receptors | 1 | 2010 | 100 | 0.080 |
Why?
|
| Genetics, Population | 3 | 2012 | 74 | 0.080 |
Why?
|
| Turkey | 1 | 2010 | 10 | 0.080 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 2009 | 147 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2008 | 75 | 0.080 |
Why?
|
| Statistics, Nonparametric | 2 | 2019 | 82 | 0.080 |
Why?
|
| Statistics as Topic | 1 | 2010 | 80 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 2 | 2010 | 270 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2015 | 393 | 0.080 |
Why?
|
| Interleukin-21 Receptor alpha Subunit | 1 | 2009 | 4 | 0.080 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2009 | 5 | 0.080 |
Why?
|
| Tilt-Table Test | 1 | 2009 | 2 | 0.080 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 102 | 0.070 |
Why?
|
| Korea | 1 | 2009 | 7 | 0.070 |
Why?
|
| Japan | 1 | 2009 | 24 | 0.070 |
Why?
|
| Keratoconus | 1 | 2008 | 8 | 0.070 |
Why?
|
| United Kingdom | 1 | 2009 | 80 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2012 | 303 | 0.070 |
Why?
|
| Demography | 1 | 2009 | 94 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2008 | 13 | 0.070 |
Why?
|
| PPAR gamma | 1 | 2008 | 29 | 0.070 |
Why?
|
| Catalase | 1 | 2008 | 49 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2010 | 125 | 0.070 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 1 | 2008 | 16 | 0.070 |
Why?
|
| Aldehydes | 1 | 2008 | 55 | 0.070 |
Why?
|
| Inflammation | 1 | 2013 | 669 | 0.070 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2009 | 168 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2012 | 2651 | 0.070 |
Why?
|
| Video-Assisted Surgery | 1 | 2007 | 2 | 0.070 |
Why?
|
| Insulin Resistance | 1 | 2009 | 176 | 0.070 |
Why?
|
| Streptokinase | 1 | 2007 | 5 | 0.070 |
Why?
|
| Thoracotomy | 1 | 2007 | 17 | 0.070 |
Why?
|
| Mice | 5 | 2018 | 4845 | 0.070 |
Why?
|
| Oklahoma | 2 | 2010 | 1062 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2019 | 1201 | 0.070 |
Why?
|
| Genetics | 1 | 2007 | 2 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2007 | 72 | 0.060 |
Why?
|
| Dendritic Cells | 2 | 2020 | 144 | 0.060 |
Why?
|
| Prognosis | 3 | 2015 | 815 | 0.060 |
Why?
|
| Infant, Newborn | 5 | 2021 | 924 | 0.060 |
Why?
|
| Genes | 2 | 2008 | 36 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2020 | 202 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 303 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2014 | 14 | 0.060 |
Why?
|
| Physical Chromosome Mapping | 1 | 2006 | 8 | 0.060 |
Why?
|
| Penetrance | 1 | 2006 | 5 | 0.060 |
Why?
|
| Abnormalities, Multiple | 1 | 2006 | 35 | 0.060 |
Why?
|
| Databases, Genetic | 2 | 2022 | 49 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 788 | 0.060 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2006 | 38 | 0.060 |
Why?
|
| Prevalence | 2 | 2020 | 523 | 0.060 |
Why?
|
| Proteins | 1 | 2008 | 255 | 0.060 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 2005 | 5 | 0.060 |
Why?
|
| China | 2 | 2016 | 64 | 0.060 |
Why?
|
| Bone and Bones | 1 | 2006 | 78 | 0.060 |
Why?
|
| Republic of Korea | 2 | 2016 | 11 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2006 | 128 | 0.060 |
Why?
|
| Community-Acquired Infections | 1 | 2025 | 31 | 0.060 |
Why?
|
| Mannose-Binding Lectin | 1 | 2004 | 4 | 0.060 |
Why?
|
| Contraceptives, Oral | 2 | 1976 | 23 | 0.050 |
Why?
|
| Antigens, Surface | 1 | 2004 | 39 | 0.050 |
Why?
|
| Complement System Proteins | 1 | 2004 | 24 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2004 | 39 | 0.050 |
Why?
|
| Receptors, IgG | 1 | 2004 | 47 | 0.050 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2004 | 38 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2004 | 77 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 1009 | 0.050 |
Why?
|
| Friedreich Ataxia | 1 | 2004 | 50 | 0.050 |
Why?
|
| Age Factors | 3 | 2015 | 740 | 0.050 |
Why?
|
| Genes, Recessive | 3 | 2004 | 21 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2019 | 2430 | 0.050 |
Why?
|
| Regeneration | 1 | 2004 | 77 | 0.050 |
Why?
|
| ROC Curve | 2 | 2018 | 144 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2004 | 84 | 0.050 |
Why?
|
| Family | 1 | 2003 | 99 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2002 | 8 | 0.050 |
Why?
|
| Survival Rate | 2 | 2015 | 433 | 0.050 |
Why?
|
| Umbilical Cord | 2 | 1973 | 35 | 0.050 |
Why?
|
| Cell Nucleolus | 1 | 2002 | 26 | 0.050 |
Why?
|
| Anemia, Hemolytic | 1 | 2002 | 22 | 0.050 |
Why?
|
| Inheritance Patterns | 1 | 2022 | 3 | 0.050 |
Why?
|
| Nuclear Family | 1 | 2002 | 12 | 0.050 |
Why?
|
| Likelihood Functions | 1 | 2002 | 27 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2015 | 468 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2002 | 211 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2002 | 113 | 0.040 |
Why?
|
| Placenta | 1 | 2021 | 78 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2020 | 112 | 0.040 |
Why?
|
| Family Health | 2 | 2016 | 71 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2025 | 538 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2015 | 631 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2020 | 83 | 0.040 |
Why?
|
| Principal Component Analysis | 2 | 2016 | 51 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2001 | 69 | 0.040 |
Why?
|
| Zebrafish | 1 | 2021 | 96 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 1672 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 121 | 0.040 |
Why?
|
| Self-Help Groups | 1 | 2019 | 16 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2021 | 256 | 0.040 |
Why?
|
| Pregnant Women | 1 | 2019 | 23 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2000 | 135 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 303 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 116 | 0.040 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2019 | 26 | 0.040 |
Why?
|
| Homozygote | 2 | 2012 | 36 | 0.040 |
Why?
|
| Repressor Proteins | 2 | 2012 | 120 | 0.040 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 2 | 2008 | 8 | 0.040 |
Why?
|
| Schizophrenia | 1 | 1998 | 51 | 0.030 |
Why?
|
| Base Sequence | 2 | 2012 | 589 | 0.030 |
Why?
|
| Infant | 1 | 2021 | 1056 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2017 | 13 | 0.030 |
Why?
|
| Algorithms | 1 | 2000 | 432 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 2017 | 39 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2017 | 66 | 0.030 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 1997 | 16 | 0.030 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2017 | 3 | 0.030 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2017 | 4 | 0.030 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2017 | 7 | 0.030 |
Why?
|
| Tachycardia | 1 | 1997 | 72 | 0.030 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2017 | 7 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2017 | 21 | 0.030 |
Why?
|
| Antiporters | 1 | 2016 | 6 | 0.030 |
Why?
|
| Phylogeography | 1 | 2016 | 19 | 0.030 |
Why?
|
| Geography | 1 | 2016 | 51 | 0.030 |
Why?
|
| Interferon Type I | 1 | 2017 | 56 | 0.030 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2016 | 8 | 0.030 |
Why?
|
| Chile | 1 | 2016 | 9 | 0.030 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2016 | 14 | 0.030 |
Why?
|
| Lipase | 1 | 1976 | 10 | 0.030 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2016 | 14 | 0.030 |
Why?
|
| Social Class | 1 | 2016 | 82 | 0.030 |
Why?
|
| HLA-DRB3 Chains | 1 | 2016 | 1 | 0.030 |
Why?
|
| HLA-DRB4 Chains | 1 | 2016 | 1 | 0.030 |
Why?
|
| HLA-DRB5 Chains | 1 | 2016 | 2 | 0.030 |
Why?
|
| HLA-DQ Antigens | 1 | 2016 | 25 | 0.030 |
Why?
|
| Peru | 1 | 2016 | 31 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2018 | 515 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2013 | 876 | 0.030 |
Why?
|
| Frameshift Mutation | 1 | 2016 | 14 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 158 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 701 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2015 | 7 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2016 | 44 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 1522 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 381 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 194 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 226 | 0.030 |
Why?
|
| Hong Kong | 1 | 2014 | 3 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 1997 | 351 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2015 | 271 | 0.030 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 1973 | 5 | 0.020 |
Why?
|
| Plasma Gases | 1 | 2013 | 4 | 0.020 |
Why?
|
| Acid Phosphatase | 1 | 1973 | 6 | 0.020 |
Why?
|
| Fibrin | 1 | 1973 | 17 | 0.020 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2013 | 36 | 0.020 |
Why?
|
| X-Ray Diffraction | 1 | 2013 | 41 | 0.020 |
Why?
|
| Labor, Obstetric | 1 | 1973 | 11 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2013 | 73 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 1973 | 31 | 0.020 |
Why?
|
| Tensile Strength | 1 | 2013 | 35 | 0.020 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2012 | 4 | 0.020 |
Why?
|
| Mad2 Proteins | 1 | 2012 | 10 | 0.020 |
Why?
|
| Hep G2 Cells | 1 | 2012 | 31 | 0.020 |
Why?
|
| Surface Properties | 1 | 2013 | 134 | 0.020 |
Why?
|
| Blood Proteins | 1 | 1973 | 68 | 0.020 |
Why?
|
| Pre-Eclampsia | 1 | 1973 | 49 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2012 | 37 | 0.020 |
Why?
|
| Anaphase | 1 | 2012 | 30 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2012 | 54 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2013 | 91 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 221 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2002 | 114 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2013 | 191 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2012 | 62 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 1992 | 36 | 0.020 |
Why?
|
| Hemizygote | 1 | 2012 | 1 | 0.020 |
Why?
|
| Genes, X-Linked | 1 | 2012 | 2 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2012 | 39 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 299 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2012 | 21 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2012 | 59 | 0.020 |
Why?
|
| TNF Receptor-Associated Factor 1 | 1 | 2012 | 5 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 2012 | 3 | 0.020 |
Why?
|
| Heterozygote | 1 | 2012 | 69 | 0.020 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2012 | 24 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2012 | 130 | 0.020 |
Why?
|
| Time Factors | 2 | 2012 | 1619 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 247 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2011 | 12 | 0.020 |
Why?
|
| Poland | 1 | 2011 | 7 | 0.020 |
Why?
|
| Meiosis | 1 | 1992 | 57 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 420 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2010 | 10 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 1994 | 1015 | 0.020 |
Why?
|
| Quinazolines | 1 | 2010 | 32 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 379 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2009 | 20 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2009 | 15 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 1033 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 166 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2008 | 79 | 0.020 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2008 | 5 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 1360 | 0.020 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2008 | 51 | 0.020 |
Why?
|
| Body Weight | 1 | 2009 | 253 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2008 | 71 | 0.020 |
Why?
|
| Erythrocyte Membrane | 1 | 2008 | 23 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 79 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2008 | 17 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2008 | 95 | 0.020 |
Why?
|
| Arabs | 1 | 2006 | 1 | 0.020 |
Why?
|
| Eye Proteins | 1 | 2008 | 207 | 0.020 |
Why?
|
| beta-Transducin Repeat-Containing Proteins | 1 | 2006 | 3 | 0.020 |
Why?
|
| Switzerland | 1 | 2006 | 6 | 0.020 |
Why?
|
| United Arab Emirates | 1 | 2006 | 3 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2006 | 15 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2008 | 310 | 0.020 |
Why?
|
| Genomics | 1 | 2007 | 126 | 0.020 |
Why?
|
| Family Characteristics | 1 | 2006 | 47 | 0.020 |
Why?
|
| Insulin | 1 | 2008 | 325 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2006 | 23 | 0.010 |
Why?
|
| Rheumatic Diseases | 1 | 2006 | 33 | 0.010 |
Why?
|
| Radiography | 1 | 2006 | 203 | 0.010 |
Why?
|
| Papaver | 1 | 1965 | 1 | 0.010 |
Why?
|
| Opium | 1 | 1965 | 2 | 0.010 |
Why?
|
| Plants, Medicinal | 1 | 1965 | 18 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2012 | 1482 | 0.010 |
Why?
|
| Amino Acids | 1 | 1965 | 85 | 0.010 |
Why?
|
| Transplantation Chimera | 1 | 2004 | 4 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2004 | 10 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 2004 | 34 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2004 | 60 | 0.010 |
Why?
|
| Fetal Blood | 1 | 2004 | 40 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2004 | 81 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2004 | 59 | 0.010 |
Why?
|
| Fetus | 1 | 2004 | 79 | 0.010 |
Why?
|
| Registries | 1 | 2005 | 398 | 0.010 |
Why?
|
| Blood Protein Electrophoresis | 2 | 1973 | 2 | 0.010 |
Why?
|
| Crithidia | 1 | 2002 | 2 | 0.010 |
Why?
|
| Antibodies | 1 | 2002 | 125 | 0.010 |
Why?
|
| Sample Size | 1 | 2000 | 17 | 0.010 |
Why?
|
| Software | 1 | 2000 | 128 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2000 | 239 | 0.010 |
Why?
|
| Purkinje Fibers | 1 | 1997 | 37 | 0.010 |
Why?
|
| Bundle-Branch Block | 1 | 1997 | 29 | 0.010 |
Why?
|
| Bundle of His | 1 | 1997 | 55 | 0.010 |
Why?
|
| Electrocardiography | 1 | 1997 | 398 | 0.010 |
Why?
|
| Mestranol | 1 | 1973 | 1 | 0.010 |
Why?
|
| Serum Globulins | 1 | 1973 | 1 | 0.010 |
Why?
|
| Ethynodiol Diacetate | 1 | 1973 | 3 | 0.010 |
Why?
|
| Serum Albumin | 1 | 1973 | 36 | 0.010 |
Why?
|
| Birth Weight | 1 | 1971 | 63 | 0.010 |
Why?
|
| Chromatography | 1 | 1965 | 9 | 0.000 |
Why?
|
| Nitrogen | 1 | 1965 | 78 | 0.000 |
Why?
|
| Cephalometry | 1 | 1971 | 28 | 0.000 |
Why?
|
| Anthropometry | 1 | 1971 | 94 | 0.000 |
Why?
|
| Parity | 1 | 1971 | 50 | 0.000 |
Why?
|
| Body Height | 1 | 1971 | 58 | 0.000 |
Why?
|
| Socioeconomic Factors | 1 | 1971 | 264 | 0.000 |
Why?
|